Evidence map›Paper›PMID 36884388›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2023

Adenosine A2A receptor activation reduces chondrocyte senescence.

Benjamin Friedman, Ane Larranaga-Vera, Cristina M Castro, Carmen Corciulo, Piul Rabbani, Bruce N Cronstein

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Get Spliced: Uniting Alternative Splicing and Arthritis.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Adenosine A2A receptor activation reduces chondrocyte senescence.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Benjamin FriedmanDivision of Rheumatology, New York University Grossman School of Medicine, New York, New York, USA.
Ane Larranaga-VeraDivision of Translational Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Cristina M CastroDivision of Translational Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Carmen CorciuloDivision of Translational Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Piul RabbaniDivision of Rheumatology, New York University Grossman School of Medicine, New York, New York, USA.
Bruce N CronsteinDivision of Rheumatology, New York University Grossman School of Medicine, New York, New York, USA.
New York University · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL, HOCHMAN, JUDITH S · 2012 to 2014
$16.8M
The Pharmacology of Dermal Fibrosis R01AR056672 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2009 to 2018
$4.6M
Purinergic Stimulation of Bone RegenerationR01AR068593 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COELHO, PAULO G, CRONSTEIN, BRUCE NEIL · 2015 to 2019
$2.8M
Purinergic Regulation of Bone MetabolismR01AR054897 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2008 to 2014
$2.1M
The Pharmacology of Dermal FibrosisR56AR056672 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2014 to 2014
$373k
NCATS NIH HHS UL1 TR000038NIAMS NIH HHS R01 AR054897NIAMS NIH HHS R01 AR056672NIAMS NIH HHS R01 AR068593NIAMS NIH HHS R56 AR056672
6 · The paper itself

Abstract

Osteoarthritis (OA) pathogenesis is associated with reduced chondrocyte homeostasis and increased levels of cartilage cellular senescence. Chondrosenescence is the development of cartilage senescence that increases with aging joints and disrupts chondrocyte homeostasis and is associated with OA. Adenosine A2A receptor (A2AR) activation in cartilage via intra-articular injection of liposomal A2AR agonist, liposomal-CGS21680, leads to cartilage regeneration in vivo and chondrocyte homeostasis. A2AR knockout mice develop early OA isolated chondrocytes demonstrate upregulated expression of cellular senescence and aging-associated genes. Based on these observations, we hypothesized that A2AR activation would ameliorate cartilage senescence. We found that A2AR stimulation of chondrocytes reduced beta-galactosidase staining and regulated levels and cell localization of common senescence mediators p21 and p16 in vitro in the human TC28a2 chondrocyte cell line. In vivo analysis similarly showed A2AR activation reduced nuclear p21 and p16 in obesity-induced OA mice injected with liposomal-CGS21680 and increased nuclear p21 and p16 in A2AR knockout mouse chondrocytes compared to wild-type mice. A2AR agonism also increased activity of the chondrocyte Sirt1/AMPK energy-sensing pathway by enhancing nuclear Sirt1 localization and upregulating T172-phosphorylated (active) AMPK protein levels. Lastly, A2AR activation in TC28a2 and primary human chondrocytes reduced wild-type p53 and concomitantly increased p53 alternative splicing leading to increase in an anti-senescent p53 variant, Δ133p53α. The results reported here indicate that A2AR signaling promotes chondrocyte homeostasis in vitro and reduces OA cartilage development in vivo by reducing chondrocyte senescence.

Indexed as

Cartilage, ArticularOsteoarthritisAdenosineAMP-Activated Protein KinasesAnimalsCellular SenescenceChondrocytesHumansMicePhenethylaminesReceptor, Adenosine A2ASirtuin 1Tumor Suppressor Protein p532-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosineAdenosineAMP-Activated Protein KinasesPhenethylaminesReceptor, Adenosine A2ASirtuin 1Tumor Suppressor Protein p53adenosineadenosine A2A receptoragingcartilagechondrocytesosteoarthritisp53 variantssenescence

Identifiers

PMID36884388
PMCPMC11977601
OpenAlexW4323533217

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.